Revvity, Inc. (NYSE:RVTY) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 8:00 AM EDT
Company Participants
Maxwell Krakowiak – Senior VP & CFO
Conference Call Participants
Brandon Couillard – Wells Fargo Securities, LLC, Research Division
Presentation
Brandon Couillard
MD & Equity Analyst
All right. Good morning. Thanks, everybody, for joining us. Welcome to the Wells Fargo Healthcare Conference. I’m Brandon Couillard. I cover life science tools and diagnostics space here at the firm. Thrilled to have Revvity back with us at the opening presentation this year. And joining us from the company, CFO, Max Krakowiak.
Maxwell Krakowiak
Senior VP & CFO
Yes. Appreciate it. Thanks for being here.
Question-and-Answer Session
Brandon Couillard
Wells Fargo Securities, LLC, Research Division
Maybe to kick things off, just starting with 2Q results. It seems like the quarter was generally in line as you expected. Outlook came down a little bit, mostly on China Diagnostics. Maybe just walk us through the quarter, how it played out relative to expectations, some of the key takeaways from your view.
Maxwell Krakowiak
Senior VP & CFO
Yes, sure. I think when we look at the second quarter performance, as you mentioned, it was roughly in line with expectations. I think things played out as anticipated. So from a growth perspective, we finished with 3% organic growth. Life Sciences was slightly above that in the mid-single-digit range. And Diagnostics was in the low single-digit range.
I think when you look at the business’ performance on the Life Sciences side, software continue to perform extremely well and excited to talk about that business a little bit further today. And then we continue to see sequential growth in our reagents business. And so we’ve got real — some good momentum in that business. Things aren’t still back to normal, but we continue to see that sequential growth.
Read the full article here
